DS
CAI

David Shaw’s Caris Life Sciences CAI Stock Holding History

David Shaw’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.65M Buy
204,818
+75,241
+58% +$1.35M ﹤0.01% 2673
2026
Q1 		$2.32M Buy
+129,577
New +$2.83M ﹤0.01% 2804
2025
Q4 		– Sell
-49,785
Closed -$1.51M – 5119
2025
Q3 		$1.51M Buy
49,785
+42,285
+564% +$1.35M ﹤0.01% 3183
2025
Q2 		$200K Buy
+7,500
New +$202K ﹤0.01% 4052

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

David Shaw's CAI Position: Q2 2026 in Review

David Shaw increased its Caris Life Sciences (CAI) stake by 58% in Q2 2026, buying an estimated $1.35M and bringing the position to 204,818 shares worth $3.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2673.

David Shaw first reported a position in CAI in Q2 2025 and has held it in 4 quarters since. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • David Shaw held 204,818 shares of Caris Life Sciences worth $3.65M as of Q2 2026.
  • David Shaw bought 75,241 Caris Life Sciences shares in Q2 2026, an estimated $1.35M.
  • Caris Life Sciences made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2673 holding.
  • David Shaw first reported a position in Caris Life Sciences in Q2 2025 and has held it in 4 quarters since.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.